With our in-house technology platform, scientific expertise in the inner ear, and network of experts, Sensorion can continually develop and optimize its pipeline and market expertise. Consequently, we are poised to expand our pipeline and facilitate other pharmaceutical collaborations.

We select and develop drug candidates from a pool of compounds in late pre-clinical and clinical stage development obtained from partnerships, collaborations and publically available drug libraries.

SENS-401 is currently being evaluated in a Phase 2 clinical trial for SSNHL and Phase 2 ready for Cisplatin-Induced ototoxicity (CIO)

20190603 pipeline


Latest news

  • 06 Jul 2020

    Sensorion appoints Dr Edwin Moses, former Ablynx CEO, as Chairman of the Board. Read

  • 17 Jun 2020

    Sensorion announces initiation of coverage by US investment bank Chardan with a "Buy" recommendation. Read

Patient center

Corporate presentation